Acasti Pharma Inc. (ACST) 2021 Stock Forecast: Bullish Outlook with -80.0% Upside

Acasti Pharma Inc. (NASDAQ: ACST) is 33.54% higher on its value in year-to-date trading and has touched a low of $0.17 and a high of $2.54 in the current 52-week trading range. The ACST stock was last observed hovering at around $0.43 in the last trading session, with the day’s gains setting it 0.02% off its average median price target of $0.25 for the next 12 months. It is also -80.0% off the consensus price target high of $0.25 offered by 1 analysts, but current levels are -80.0% lower than the price target low of $0.25 for the same period.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $0.45, the stock is 42.40% and 68.62% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 13.15 million and changing 3.03% at the moment leaves the stock -2.70% off its SMA200. ACST registered -81.37% loss for a year compared to 6-month loss of -41.35%. The firm has a 50-day simple moving average (SMA 50) of $0.2997 and a 200-day simple moving average (SMA200) of $0.4028.

The stock witnessed a 42.76% gain in the last 1 month and extending the period to 3 months gives it a 109.76%, and is 44.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 23.09% over the week and 16.41% over the month.

Distance from 52-week low is 161.49% and -82.40% from its 52-week high.

Acasti Pharma Inc. (ACST) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Acasti Pharma Inc. (ACST) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Acasti Pharma Inc. is expected to release its quarterly report on 06/30/2021 and quarterly earnings per share for the current quarter are estimated at -$0.16.The EPS is expected to grow by 30.30% this year.

Acasti Pharma Inc. (ACST) Top Institutional Holders

27 institutions hold shares in Acasti Pharma Inc. (ACST), with 8.37M shares held by insiders accounting for 8.64% while institutional investors hold 1.81% of the company’s shares. The shares outstanding are 96.89M, and float is at 93.53M with Short Float at 0.54%. Institutions hold 1.66% of the Float.

The top institutional shareholder in the company is Two Sigma Advisers, LP with over 0.28 million shares valued at $56816.0. The investor’s holdings represent 0.26% of the ACST Shares outstanding. As of Sep 29, 2020, the second largest holder is Bank of Montreal/Can/ with 0.25 million shares valued at $50430.0 to account for 0.23% of the shares outstanding. The other top investors are Oppenheimer & Company Inc. which holds 0.19 million shares representing 0.18% and valued at over $38996.0, while Virtu Financial LLC holds 0.12% of the shares totaling 0.13 million with a market value of $26886.0.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Acasti Pharma Inc. (ACST): Who are the competitors?

Omeros Corporation (OMER) is 12.23% up on the 1-year trading charts. Short interest in the company’s stock has fallen -7.25% from the last report on Nov 12, 2020 to stand at a total of 0.54 million short shares sold with a short interest ratio of 0.04.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free